Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors (NCT05983432)

🧪 Interventions in This Study

• BL-B01D1 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (39 Sites)

Showing the first 25 of 39 sites.

• Beverly Hills Cancer Center — Beverly Hills, California
• City of Hope Cancer Center — Duarte, California
• Chao Family Comprehensive Cancer Care and Ambulatory Care — Irvine, California
• Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
• University of California Irvine Medical Center — Orange, California
• UCLA Santa Monica — Santa Monica, California
• University of Colorado Cancer Center — Aurora, Colorado
• Yale University, Yale Cancer Center — New Haven, Connecticut
• Georgetown University Medical Center — Washington D.C., District of Columbia
• Sylvester Comprehensive Cancer Center — Miami, Florida
• Sara Cannon Research Institute Lake Nona — Orlando, Florida
• Hematology - Oncology Associates of the Treasure Coast — Port Saint Lucie, Florida
• Northwestern University Feinberg School of Medicine — Chicago, Illinois
• University of Iowa Hospital and Clinics — Iowa City, Iowa
• Norton Cancer Institute — Louisville, Kentucky
• Massachusetts General Hospital — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Memorial Sloan Kettering Cancer Center Head Neck Services — New York, New York
• PRISMA Health/ITOR — Greenville, South Carolina
• Sarah Cannon - Tennessee Oncology — Nashville, Tennessee
• Oncology Consultants, P.A. — Houston, Texas
• University of Texas M.D. Anderson Cancer Center — Houston, Texas
• Virginia Cancer Specialists — Fairfax, Virginia
• University of Washington Fred Hutchinson — Seattle, Washington
• Centre Léon Bérard — Lyon,

📞 Contact the Study Coordinator

Phone: (425) 453-6841

Email: tara.barrineau@systimmune.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non Small Cell Lung Cancer

• The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
• A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer — Middletown, New Jersey
• Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Beverly Hills, California
• Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
• Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease — Edmonton, Alberta
• A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer — Springdale, Arkansas

Explore by condition: All Non Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.